Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
Gupta S, Zhou P, Hassoun H, Kewalramani T, Reich L, Costello S, Drake L, Klimek V, Dhodapkar M, Teruya-Feldstein J, Hedvat C, Kalakonda N, Fleisher M, Filippa D, Qin J, Nimer SD, Comenzo RL. Gupta S, et al. Among authors: hassoun h. Bone Marrow Transplant. 2005 Mar;35(5):441-7. doi: 10.1038/sj.bmt.1704779. Bone Marrow Transplant. 2005. PMID: 15640822 Clinical Trial.
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL. Hassoun H, et al. Br J Haematol. 2006 Jan;132(2):155-61. doi: 10.1111/j.1365-2141.2005.05848.x. Br J Haematol. 2006. PMID: 16398649 Free article. Clinical Trial.
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL. Cohen AD, et al. Among authors: hassoun h. Br J Haematol. 2007 Oct;139(2):224-33. doi: 10.1111/j.1365-2141.2007.06783.x. Br J Haematol. 2007. PMID: 17897298 Free article. Clinical Trial.
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone.
Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, Maurer MS, Steingart RM, Cohen AD, Comenzo RL. Lebovic D, et al. Among authors: hassoun h. Br J Haematol. 2008 Nov;143(3):369-73. doi: 10.1111/j.1365-2141.2008.07327.x. Epub 2008 Aug 4. Br J Haematol. 2008. PMID: 18691169 Free article. Clinical Trial.
Osteomalacia due to adult Fanconi syndrome in multiple myeloma.
Bhutani M, Klein MJ, Glezerman I, Landau H, Rosenzweig M, Hassoun H. Bhutani M, et al. Among authors: hassoun h. Leuk Lymphoma. 2011 Mar;52(3):536-8. doi: 10.3109/10428194.2010.540459. Epub 2011 Feb 1. Leuk Lymphoma. 2011. PMID: 21281229 No abstract available.
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL. Landau H, et al. Among authors: hassoun h. Leuk Lymphoma. 2012 Feb;53(2):275-81. doi: 10.3109/10428194.2011.606943. Epub 2011 Sep 23. Leuk Lymphoma. 2012. PMID: 21824051 Clinical Trial.
194 results